(Imagen generada únicamente con fines ilustrativos)
Un «fármaco superventas» es un producto farmacéutico que genera más de mil millones de dólares en ventas anuales para su fabricante. Este modelo de negocio ha impulsado históricamente la industria farmacéutica, centrando la investigación y el desarrollo (I+D) en afecciones crónicas comunes para maximizar los ingresos protegidos por patentes. Estos ingresos financian la I+D de nuevos fármacos, creando un ciclo de innovación y altas ganancias.
The blockbuster model became the dominant strategy for large pharmaceutical companies in the late 20th century. The model relies on developing and patenting a drug that can treat a widespread chronic condition, such as high cholesterol (e.g., Lipitor), acid reflux (e.g., Prilosec), or depression (e.g., Prozac). Once approved, the company launches a massive marketing campaign aimed at both physicians and consumers (in countries where direct-to-consumer advertising is legal). The goal is to achieve widespread prescription and capture a large market share. The drug’s patent provides a period of market exclusivity, typically 20 years from the filing date, during which the company can charge high prices without competition from generic versions. The enormous profits generated during this period are used to recoup the substantial R&D investment—often exceeding $1 billion per approved drug—and to fund the development of the next generation of potential blockbusters. However, this model faces significant challenges. The “low-hanging fruit” of common diseases has largely been addressed, making new discoveries more difficult. Increased pressure from payers (governments and insurance companies) to control costs, and the looming “patent cliff” (when patents for multiple blockbuster drugs expire around the same time), have forced the industry to reconsider this strategy. Many companies are now shifting towards developing more specialized, high-value drugs for smaller patient populations, such as orphan drugs for rare diseases or personalized cancer therapies, which can command even higher prices per patient.
Debido al bloqueo del tráfico generado por bots, que actualmente supera los 40.000 al día, este contenido está reservado para los miembros de la comunidad.
> Iniciar sesión < o > Registrarse < (100% gratis) para acceder a esto, al igual que a todo el demás contenido y herramientas restringidos.
Modelo de fármaco de gran éxito
(Si la fecha es desconocida o no es relevante, por ejemplo "mecánica de fluidos", se proporciona una estimación redondeada de su aparición notable)
Las imágenes a tamaño completo y las descargas sólo están disponibles, 100% gratis, para los miembros registrados.
> Acceso <
